{"id":43672,"date":"2025-10-17T14:42:39","date_gmt":"2025-10-17T06:42:39","guid":{"rendered":"https:\/\/flcube.com\/?p=43672"},"modified":"2025-10-17T14:42:40","modified_gmt":"2025-10-17T06:42:40","slug":"viatris-acquires-aculys-pharma-to-secure-japanese-rights-for-pitolisant-and-spydia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43672","title":{"rendered":"Viatris Acquires Aculys Pharma to Secure Japanese Rights for Pitolisant and Spydia"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Viatris Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/VTRS:NASDAQ\">NASDAQ: VTRS<\/a>) today announced the completion of its acquisition of <strong>Aculys Pharma<\/strong>, gaining exclusive development and commercialization rights to two central nervous system (CNS) assets\u2014<strong>Pitolisant<\/strong> (Wakix) and <strong>Spydia<\/strong> (diazepam nasal spray). The deal expands Viatris\u2019 innovative portfolio in Japan and positions the company to capture a growing market for narcolepsy, obstructive sleep apnea, and status epilepticus therapies.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-deal-highlights\">Deal Highlights<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquisition Structure<\/strong><\/td><td>Upfront payment to Aculys shareholders; milestone\u2011based additional consideration; royalty on net sales<\/td><\/tr><tr><td><strong>Assets<\/strong><\/td><td>1. <strong>Pitolisant<\/strong> \u2013 selective H3 receptor inverse agonist (Wakix) for narcolepsy &amp; OSAS<\/td><\/tr><tr><td><\/td><td>2. <strong>Spydia<\/strong> (diazepam nasal spray) \u2013 first intranasal anti\u2011seizure rescue in Japan<\/td><\/tr><tr><td><strong>Geographic Scope<\/strong><\/td><td>Exclusive development\/commercialization in Japan and selected APAC markets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pitolisant-a-breakthrough-narcolepsy-treatment\">Pitolisant \u2013 A Breakthrough Narcolepsy Treatment<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Status<\/strong> \u2013 Orphan Drug (EMA &amp; FDA) and FDA Breakthrough Therapy designation.<\/li>\n\n\n\n<li><strong>Commercial Track Record<\/strong> \u2013 Approved in 38 countries (incl. U.S. &amp; EU) for narcolepsy; 29 EU countries for OSAS.<\/li>\n\n\n\n<li><strong>Strategic Value<\/strong> \u2013 Aculys\u2019 partnership with Bioprojet granted Viatris exclusive Japanese rights, enabling rapid market entry and revenue generation.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-spydia-first-intranasal-rescue-for-status-epilepticus\">Spydia \u2013 First Intranasal Rescue for Status Epilepticus<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Product Profile<\/strong> \u2013 5\u202fmg, 7.5\u202fmg, and 10\u202fmg diazepam nasal spray for patients \u2265\u202f2\u202fyears.<\/li>\n\n\n\n<li><strong>Regulatory Milestone<\/strong> \u2013 First intranasal anti\u2011seizure drug approved in Japan (June\u202f2025).<\/li>\n\n\n\n<li><strong>Market Opportunity<\/strong> \u2013 First out\u2011of\u2011hospital rescue medication for adults, addressing a critical unmet need in acute seizure management.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-implications-for-viatris\">Strategic Implications for Viatris<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Diversification<\/strong> \u2013 Adds two high\u2011barrier, high\u2011margin CNS products to Viatris\u2019 global lineup.<\/li>\n\n\n\n<li><strong>Market Expansion<\/strong> \u2013 Leverages Aculys\u2019 established APAC presence to accelerate commercialization in Japan and beyond.<\/li>\n\n\n\n<li><strong>Revenue Upside<\/strong> \u2013 Milestone and royalty structures align long\u2011term upside with commercial success.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Viatris Inc. (NASDAQ: VTRS) today announced the completion of its acquisition of Aculys Pharma, gaining&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43675,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[4397,1018,24,207],"class_list":["post-43672","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-aculys-pharma","tag-nasdaq-vtrs","tag-rare-orphan-disease-drugs","tag-viatris"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Viatris Acquires Aculys Pharma to Secure Japanese Rights for Pitolisant and Spydia - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Viatris Inc. (NASDAQ: VTRS) today announced the completion of its acquisition of Aculys Pharma, gaining exclusive development and commercialization rights to two central nervous system (CNS) assets\u2014Pitolisant (Wakix) and Spydia (diazepam nasal spray). The deal expands Viatris\u2019 innovative portfolio in Japan and positions the company to capture a growing market for narcolepsy, obstructive sleep apnea, and status epilepticus therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43672\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Viatris Acquires Aculys Pharma to Secure Japanese Rights for Pitolisant and Spydia\" \/>\n<meta property=\"og:description\" content=\"Viatris Inc. (NASDAQ: VTRS) today announced the completion of its acquisition of Aculys Pharma, gaining exclusive development and commercialization rights to two central nervous system (CNS) assets\u2014Pitolisant (Wakix) and Spydia (diazepam nasal spray). The deal expands Viatris\u2019 innovative portfolio in Japan and positions the company to capture a growing market for narcolepsy, obstructive sleep apnea, and status epilepticus therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43672\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-17T06:42:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-17T06:42:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1706.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43672#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43672\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Viatris Acquires Aculys Pharma to Secure Japanese Rights for Pitolisant and Spydia\",\"datePublished\":\"2025-10-17T06:42:39+00:00\",\"dateModified\":\"2025-10-17T06:42:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43672\"},\"wordCount\":294,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43672#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1706.webp\",\"keywords\":[\"Aculys Pharma\",\"NASDAQ: VTRS\",\"Rare \\\/ orphan disease drugs\",\"Viatris\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43672#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43672\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43672\",\"name\":\"Viatris Acquires Aculys Pharma to Secure Japanese Rights for Pitolisant and Spydia - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43672#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43672#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1706.webp\",\"datePublished\":\"2025-10-17T06:42:39+00:00\",\"dateModified\":\"2025-10-17T06:42:40+00:00\",\"description\":\"Viatris Inc. (NASDAQ: VTRS) today announced the completion of its acquisition of Aculys Pharma, gaining exclusive development and commercialization rights to two central nervous system (CNS) assets\u2014Pitolisant (Wakix) and Spydia (diazepam nasal spray). The deal expands Viatris\u2019 innovative portfolio in Japan and positions the company to capture a growing market for narcolepsy, obstructive sleep apnea, and status epilepticus therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43672#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43672\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43672#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1706.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1706.webp\",\"width\":1080,\"height\":608,\"caption\":\"Viatris Acquires Aculys Pharma to Secure Japanese Rights for Pitolisant and Spydia\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43672#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Viatris Acquires Aculys Pharma to Secure Japanese Rights for Pitolisant and Spydia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Viatris Acquires Aculys Pharma to Secure Japanese Rights for Pitolisant and Spydia - Insight, China&#039;s Pharmaceutical Industry","description":"Viatris Inc. (NASDAQ: VTRS) today announced the completion of its acquisition of Aculys Pharma, gaining exclusive development and commercialization rights to two central nervous system (CNS) assets\u2014Pitolisant (Wakix) and Spydia (diazepam nasal spray). The deal expands Viatris\u2019 innovative portfolio in Japan and positions the company to capture a growing market for narcolepsy, obstructive sleep apnea, and status epilepticus therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43672","og_locale":"en_US","og_type":"article","og_title":"Viatris Acquires Aculys Pharma to Secure Japanese Rights for Pitolisant and Spydia","og_description":"Viatris Inc. (NASDAQ: VTRS) today announced the completion of its acquisition of Aculys Pharma, gaining exclusive development and commercialization rights to two central nervous system (CNS) assets\u2014Pitolisant (Wakix) and Spydia (diazepam nasal spray). The deal expands Viatris\u2019 innovative portfolio in Japan and positions the company to capture a growing market for narcolepsy, obstructive sleep apnea, and status epilepticus therapies.","og_url":"https:\/\/flcube.com\/?p=43672","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-17T06:42:39+00:00","article_modified_time":"2025-10-17T06:42:40+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1706.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43672#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43672"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Viatris Acquires Aculys Pharma to Secure Japanese Rights for Pitolisant and Spydia","datePublished":"2025-10-17T06:42:39+00:00","dateModified":"2025-10-17T06:42:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43672"},"wordCount":294,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43672#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1706.webp","keywords":["Aculys Pharma","NASDAQ: VTRS","Rare \/ orphan disease drugs","Viatris"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43672#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43672","url":"https:\/\/flcube.com\/?p=43672","name":"Viatris Acquires Aculys Pharma to Secure Japanese Rights for Pitolisant and Spydia - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43672#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43672#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1706.webp","datePublished":"2025-10-17T06:42:39+00:00","dateModified":"2025-10-17T06:42:40+00:00","description":"Viatris Inc. (NASDAQ: VTRS) today announced the completion of its acquisition of Aculys Pharma, gaining exclusive development and commercialization rights to two central nervous system (CNS) assets\u2014Pitolisant (Wakix) and Spydia (diazepam nasal spray). The deal expands Viatris\u2019 innovative portfolio in Japan and positions the company to capture a growing market for narcolepsy, obstructive sleep apnea, and status epilepticus therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43672#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43672"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43672#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1706.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1706.webp","width":1080,"height":608,"caption":"Viatris Acquires Aculys Pharma to Secure Japanese Rights for Pitolisant and Spydia"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43672#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Viatris Acquires Aculys Pharma to Secure Japanese Rights for Pitolisant and Spydia"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1706.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43672","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43672"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43672\/revisions"}],"predecessor-version":[{"id":43676,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43672\/revisions\/43676"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43675"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43672"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43672"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43672"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}